Novartis: Advisory Panel Voted Against RLX030 For Acute Heart Failure RTT News Swiss pharmaceutical giant Novartis AG (NVS: Quote) Thursday said the US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee or CRDAC voted against approval for RLX030 or serelaxin for the treatment of acute heart ... |
